Connect Biopharma says Phase 2 trial shows rademikibart cuts COPD treatment failure rate 81% through Week 4

Bitget2026/09/30 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Connect Biopharma reported positive preliminary topline results from a global Phase 2 trial of rademikibart in acute COPD flare-ups.
Results have been presented already, with a conference call scheduled for today at 8:00 a.m. ET.
The drug cut post-flare treatment failures versus placebo, with fewer repeat medical visits in the month following dosing.
It also lowered new moderate-to-severe flare-ups, with no return emergency visits or hospitalizations reported in the treatment arm.
The company plans to seek FDA alignment on a Phase 3 registrational program for rademikibart as an add-on COPD therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836501) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Connect Biopharma says Phase 2 trial shows rademikibart cuts COPD treatment failure rate 81% through Week 4

You may also like

Crypto prices